Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)
Ernesto Maddaloni(Oxford Centre for Diabetes, Endocrinology and Metabolism), Marco Ridolfi, Francesco Pugliese(Sapienza University of Rome), Alban Rugova(Policlinico Umberto I), Lucia Coraggio, Giuseppe Pascarella(Università Campus Bio-Medico), Cecilia Luordi(Policlinico Umberto I), Gabriella d’Ettorre(Policlinico Umberto I), Luigi Celani(Sapienza University of Rome), Ambrogio Curtolo(Sapienza University of Rome), Raffaella Buzzetti(St Bartholomew's Hospital), Raissa Aronica, Francesco Alessandri(Sapienza University of Rome), Claudia D’Agostino(Sapienza University of Rome), Matteo Candy, Claudio Maria Mastroianni(Sapienza University of Rome), Gregorio Egidio Recchia(Sapienza University of Rome), Alessandra Caputi, Valeria Belvisi(Policlinico Umberto I), Giancarlo Ceccarelli(International Organization for Migration), Maria Rosa Ciardi(Sapienza University of Rome), Monica Rocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Federica Alessi(Policlinico Umberto I), Rury R. Holman(University of Oxford), Carmen Mignogna(Policlinico Umberto I), Ivano Mezzaroma(Istituto Superiore di Sanità), Lucio Gnessi(Sapienza University of Rome), Andrea Lenzi(Canadian Obesity Network), Anna Carrara, Valeria Filippi, Gaetano Leto(Ospedale Santa Maria Goretti), Felice Eugenio Agrò(Università Campus Bio-Medico), Elena Casali, Luca D’Onofrio(Policlinico Umberto I), Chiara Moretti(University of Padua), Camilla Ajassa, Paolo Pozzilli(St Bartholomew's Hospital), Gabriella De Girolamo(Sapienza University of Rome), Francesca De Giorgi, Eugenio Nelson Cavallari(Policlinico Umberto I), Miriam Lichtner(Sapienza University of Rome)
Cited by 114
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
|The Lancet Diabetes & Endocrinology|2017|591
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2001|470